The Company operates through two geographical segments: North America and China (P.R.C), jointly producing and selling products in these regions. For the year ended September 30, 2025, the Company reported four business segments: Homology of Medicine and Food Series, Computing Power Product Series, Maca Product Series, and others. The Chief Financial Officer, serving as the chief operating decision maker, reviews the Company's overall assets, operating results, and financial metrics to allocate resources and assess performance.
Segment financial results for the year ended September 30, 2025, include net revenues of $6,349,252 for Homology of Medicine and Food Series, $3,804,691 for Computing Power Product Series, and $144,726 for Maca Product Series, totaling $10,298,669 before eliminations. The Company also reports costs, gross profit, operating expenses, allowance for credit loss, inventory impairment loss, loss from operations, fair value variation, loss on acquisition, goodwill impairment, other income, other expenses, and segment loss for these segments.
For the year ended September 30, 2024, only the Maca Product Series was reported, with net revenues of $1,930,291. Related financial results included cost of revenue, gross profit, operating expenses, allowance for credit loss, inventory write-down, impairment loss on assets held for sale, loss from operations, fair value variation, loss from investment, other income, other expenses, and net interest expense.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
974.44 %